Rinvoq bags FDA green light

AbbVie has announced the US Food and Drug Administration (FDA) approval of Rinvoq (upadacitinib) for moderate to severe active rheumatoid arthritis (RA). In the SELECT programme, the oral JAK inhibitor met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis, and significantly inhibited radiographic progression even without methotrexate.
Read more...

;